Traynor Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$462K Buy
19,204
+1,443
+8% +$37.7K 0.02% 206
2026
Q1
$493K Sell
17,761
-9,219
-34% -$245K 0.03% 175
2025
Q4
$672K Sell
26,980
-2,797
-9% -$70.5K 0.04% 156
2025
Q3
$759K Sell
29,777
-119
-0.4% -$2.94K 0.04% 147
2025
Q2
$749K Buy
29,896
+3,157
+12% +$73.6K 0.05% 104
2025
Q1
$678K Sell
26,739
-2,062
-7% -$54K 0.06% 110
2024
Q4
$764K Buy
28,801
+1,473
+5% +$40K 0.05% 117
2024
Q3
$791K Buy
27,328
+1,445
+6% +$42.2K 0.05% 114
2024
Q2
$724K Buy
25,883
+4,104
+19% +$113K 0.05% 110
2024
Q1
$604K Buy
21,779
+59
+0.3% +$1.64K 0.05% 131
2023
Q4
$625K Sell
21,720
-11,893
-35% -$360K 0.06% 121
2023
Q3
$1.11M Buy
33,613
+2,421
+8% +$85.6K 0.14% 77
2023
Q2
$1.14M Sell
31,192
-2,313
-7% -$90K 0.14% 78
2023
Q1
$1.37M Buy
33,505
+4,719
+16% +$204K 0.2% 66
2022
Q4
$1.48M Sell
28,786
-952
-3% -$45.6K 0.21% 64
2022
Q3
$1.3M Buy
29,738
+1,059
+4% +$51.5K 0.23% 57
2022
Q2
$1.5M Buy
28,679
+104
+0.4% +$5.3K 0.26% 55
2022
Q1
$1.48M Sell
28,575
-93,676
-77% -$4.86M 0.19% 61
2021
Q4
$7.22M Buy
122,251
+5,818
+5% +$288K 0.85% 24
2021
Q3
$5.01M Sell
116,433
-347
-0.3% -$15.4K 0.69% 36
2021
Q2
$4.64M Sell
116,780
-2,581
-2% -$100K 0.65% 38
2021
Q1
$4.32M Sell
119,361
-1,705
-1% -$60.5K 0.71% 37
2020
Q4
$4.46M Buy
121,066
+27,809
+30% +$1.02M 0.79% 31
2020
Q3
$3.38M Buy
93,257
+17,622
+23% +$618K 0.77% 29
2020
Q2
$2.35M Buy
75,635
+22,760
+43% +$773K 0.56% 40
2020
Q1
$1.64M Buy
52,875
+12,377
+31% +$422K 0.58% 35
2019
Q4
$1.5M Buy
40,498
+4,082
+11% +$145K 0.4% 54
2019
Q3
$1.24M Buy
36,416
+4,116
+13% +$150K 0.39% 57
2019
Q2
$1.34M Buy
32,300
+504
+2% +$20K 0.44% 51
2019
Q1
$1.28M Buy
31,796
+1,606
+5% +$64.3K 0.43% 47
2018
Q4
$1.25M Sell
30,190
-1,338
-4% -$55.5K 0.52% 39
2018
Q3
$1.32M Sell
31,528
-601
-2% -$23.1K 0.43% 44
2018
Q2
$1.11M Sell
32,129
-2,080
-6% -$71.1K 0.4% 43
2018
Q1
$1.15M Buy
34,209
+1,608
+5% +$55.3K 0.47% 41
2017
Q4
$1.12M Sell
32,601
-185
-0.6% -$6.31K 0.48% 46
2017
Q3
$1.11M Sell
32,786
-257
-0.8% -$8.26K 0.53% 42
2017
Q2
$1.03M Sell
33,043
-682
-2% -$21.5K 0.51% 42
2017
Q1
$1.08M Buy
33,725
+391
+1% +$12.3K 0.6% 34
2016
Q4
$990K Buy
33,334
+2,774
+9% +$84.7K 0.66% 34
2016
Q3
$945K Buy
30,560
+1,304
+4% +$43.6K 0.67% 36
2016
Q2
$993K Sell
29,256
-35
-0.1% -$1.12K 0.78% 32
2016
Q1
$823K Buy
29,291
+268
+0.9% +$7.66K 0.66% 34
2015
Q4
$888K Sell
29,023
-942
-3% -$29.6K 0.64% 39
2015
Q3
$893K Sell
29,965
-143
-0.5% -$4.58K 0.77% 28
2015
Q2
$957K Buy
30,108
+20,430
+211% +$666K 0.8% 26
2015
Q1
$319K Sell
9,678
-273
-3% -$8.68K 0.31% 72
2014
Q4
$294K Buy
+9,951
New +$285K 0.34% 73

Other funds holding PFE

Traynor Capital Management's PFE Position: Q2 2026 in Review

Traynor Capital Management increased its Pfizer (PFE) stake by 8.1% in Q2 2026, buying an estimated $37.7K and bringing the position to 19,204 shares worth $462K. The position accounts for 0.02% of the portfolio, ranked #206.

Traynor Capital Management first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.22M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Traynor Capital Management held 19,204 shares of Pfizer worth $462K as of Q2 2026.
  • Traynor Capital Management bought 1,443 Pfizer shares in Q2 2026, an estimated $37.7K.
  • Pfizer made up 0.02% of Traynor Capital Management's portfolio in Q2 2026, its #206 holding.
  • Traynor Capital Management first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
  • Traynor Capital Management's Pfizer position peaked at $7.22M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.